Hypertrophic cardiomyopathy (HCM) is characterized by abnormal thickening of the heart muscle and can be associated with excessive cardiac contractility, impaired relaxation, and obstruction of blood flow from the heart. Historically, treatment has largely focused on managing these consequences through beta blockers and other therapies that reduce heart rate or obstruction, together with supportive treatment when complications such as congestive heart failure develop. 

Advances in understanding the sarcomere, the molecular machinery responsible for heart muscle contraction, have enabled more targeted therapeutic approaches. Cardiac myosin inhibitors can directly reduce excessive contractile activity and have emerged as an important treatment strategy for human HCM, demonstrating the clinical potential of modulating the underlying contractile mechanism. 

This progress creates an opportunity to translate sarcomere-targeted and contractility-modulating approaches to feline HCM, which shares important physiological and molecular features with the human disease. A key challenge, however, is achieving a duration of therapeutic exposure or effect that enables practical treatment in cats. Existing approaches require frequent dosing, creating a need for molecules or technologies capable of supporting once-weekly or longer dosing while maintaining appropriate activity and safety.